Archive
Archive
Autosomal dominant polycystic kidney disease
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
PUBLISHED: 29 January 2016
Important update (2019): please note that this document was published on 29 January 2016 and considered the Tempo 3:4 Trial and former EMA licence regarding Tolvaptan. Since then, the Tempo 4:4 results have been published, there has been a new trial (REPRISE) and an update of the EMA licence, which means that this ERBP document is outdated. ERBP cannot confirm at this time whether an update will follow.
European Best Practice Guidelines (EBPG)
European Best Practice Guidelines for Anaemia in patients with Chronic Renal Failure
Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure
PUBLISHED: 1 May 2004
European Best Practice Guideline for Anaemia
PUBLISHED: 1 May 2004
European Best Practice Guidelines for Haemodialysis
European Best Practice Guideline for Haemodialysis Part 1
PUBLISHED: 1 July 2002
European Best Practice Guideline for Haemodialysis Part 2
PUBLISHED: 1 May 2007
European Best Practice Guidelines for Transplantation
European Best Practice Guideline for Transplantation Part 1
PUBLISHED: 2 December 2000
European Best Practice Guideline for Transplantation Part 2
PUBLISHED: 1 April 2002
European Best Practice Guidelines for Peritoneal Dialysis
European Best Practice Guidelines for Peritoneal Dialysis
PUBLISHED: 1 December 2005
ERA Operative Headquarters
Strada dei Mercati 16/A
I-43126 Parma – Italy
Phone: +39 0521 989078
E-mail: secretariat@era-online.org
ERA Registered Office
c/o PKF Littlejohn, 15 Westferry Circus, Canary Wharf
London E14 4HD – United Kingdom